Abstract 2698 Identifying HER2 Expression in Osteosarcoma as Immunotherapy Target

Background. Osteosarcoma (OS) is the most prevalent pediatric primary malignant bone tumor and ranks as the third most common cancer in adolescents, impacting hundreds of individuals under the age of 20 annually. Current standard osteosarcoma treatment involves neoadjuvant chemotherapy, surgical resection, and radiation therapy. Despite these interventions, osteosarcoma has a poor prognosis, prompting the exploration of immunotherapy as a potential treatment option. One promising candidate for osteosarcoma immunotherapy is HER2, although findings from multiple studies have been inconclusive.